Procter & Gamble Health quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	364	339	+7.4%
EBITDA	99.6	90.3	+10.3%
EBITDA margin	27.4%	26.7%	+0.7 pts
Profit before tax	129	88.8	+45.4%
Net profit	96.2	66.2	+45.3%
EPS	₹57.92	₹39.87	+45.3%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	364	370	374	325	339	311	310	313	284	252	310	305	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	3.9	4.0	4.4	5.0	4.0	3.1	4.0	3.3	2.1	2.3	5.2	6.1
	368	374	378	330	343	314	314	317	286	255	315	311
	80.3	85.2	84.5	78.1	59.5	90.8	61.6	48.2	67.4	64.7	70.8	87.3
	24.6	22.3	13.3	10.6	24.3	13.7	13.3	20.2	18.5	11.1	8.4	1.4
	−8.7	−14.6	12.0	−20.4	10.1	−5.8	0.9	19.7	−6.8	−1.9	11.2	−1.6
	60.4	50.9	61.8	53.9	56.0	48.8	47.1	46.2	48.6	48.5	57.4	60.6
	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2
	6.0	6.2	5.9	6.1	5.4	5.4	5.6	5.8	7.2	6.8	6.9	6.5
	108	91.1	91.8	82.4	98.4	82.6	63.6	65.1	108	62.7	60.5	68.5
	270	241	269	211	254	236	192	205	243	192	215	223
	99.6	136	110	120	90.3	80.9	123	114	48.3	67.4	102	88.7
	93.6	129	105	114	84.9	75.6	118	108	41.1	60.6	94.7	82.2
Profit
	97.3	133	109	119	88.8	78.5	122	111	43.0	62.7	99.7	88.1
	31.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−20.2	0.0	0.0	0.0
	129	133	109	119	88.8	78.5	122	111	22.8	62.7	99.7	88.1
	31.0	32.1	32.9	30.5	22.9	20.7	29.0	28.0	12.8	16.3	29.6	22.3
	1.9	6.5	−1.7	−0.1	−0.3	−3.4	1.8	1.1	−6.7	−0.1	−1.9	0.2
	33.0	38.6	31.2	30.5	22.6	17.4	30.8	29.1	6.1	16.2	27.7	22.5
	96.2	94.6	77.6	88.5	66.2	61.2	90.9	82.3	16.8	46.6	72.1	65.6
	96.2	94.6	77.6	88.5	66.2	61.2	90.9	82.3	16.8	46.6	72.1	65.6
	0.3	−2.9	0.9	2.4	−0.7	−0.8	−2.0	0.2	−1.0	1.3	0.9	−0.5
	96.5	91.7	78.5	91.0	65.5	60.4	88.9	82.5	15.8	47.9	72.9	65.1
Per share
	₹57.92	₹56.99	₹46.74	₹53.34	₹39.87	₹36.86	₹54.76	₹49.60	₹10.11	₹28.00	₹43.40	₹39.50
	₹57.92	₹56.99	₹46.74	₹53.34	₹39.87	₹36.86	₹54.76	₹49.60	₹10.11	₹28.00	₹43.40	₹39.50
Other comprehensive income — detail
	0.3	−2.9	0.9	2.4	−0.7	−0.8	—	—	—	—	—	—
	0.4	−3.9	1.2	3.2	−0.9	−1.1	−2.7	0.2	−1.3	1.8	1.2	−0.7
	0.1	−1.0	0.3	0.8	−0.2	−0.3	—	—	—	—	—	—
	—	—	—	—	—	—	−0.7	0.1	−0.3	0.4	0.3	0.0
	—	—	—	—	—	—	0.0	0.0	0.0	0.0	—	−0.2
Per share — as-filed variants
	₹57.92	₹56.99	₹46.74	₹53.34	₹39.87	₹36.86	₹54.76	₹49.60	₹10.11	₹28.00	₹43.40	₹39.50
	₹57.92	₹56.99	₹46.74	₹53.34	₹39.87	₹36.86	₹54.76	₹49.60	₹10.11	₹28.00	₹43.40	₹39.50
Regulatory disclosures — filed alongside, not part of the P&L
	—	278	—	−39.1	—	113	—	—	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	267	278	264	257	245	212	234	225	205	179	220	218
	73.5%	74.9%	70.6%	78.9%	72.3%	68.3%	75.6%	71.9%	72.1%	70.7%	70.8%	71.4%
Adjusted (ex-exceptional items) — derived
	97.3	133	109	119	88.8	78.5	122	111	43.0	62.7	99.7	88.1
	31.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−20.2	0.0	0.0	0.0
	72.5	94.6	77.6	88.5	66.2	61.2	90.9	82.3	31.6	46.6	72.1	65.6
	₹43.66	₹56.99	₹46.74	₹53.34	₹39.87	₹36.86	₹54.76	₹49.60	₹19.05	₹28.00	₹43.40	₹39.50

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

PGHL₹5,399.00

Procter & Gamble Health Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSANOFICONR SANOFI SENORES INNOVACAP MOREPENLAB IOLCP FDC ASTRAZENMcap ₹8,962 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	304.9	310.0	252.5	283.9	313.4	309.8	311.0	338.7	324.9	373.9	370.5	363.7
Other Income	6.1	5.2	2.3	2.1	3.3	4.0	3.1	4.0	5.0	4.4	4.0	3.9
Total Income	311.0	315.2	254.8	286.0	316.7	313.7	314.1	342.8	329.9	378.2	374.5	367.6
Expenses
+ Cost of Materials Consumed	87.3	70.8	64.7	67.4	48.2	61.6	90.8	59.5	78.1	84.5	85.2	80.3
+ Purchases of Stock-in-Trade	1.4	8.4	11.1	18.5	20.2	13.3	13.7	24.3	10.6	13.3	22.3	24.6
+ Changes in Inventories	-1.6	11.2	-1.9	-6.8	19.7	0.9	-5.8	10.1	-20.4	12.0	-14.6	-8.7
+ Employee Benefit Expense	60.6	57.4	48.5	48.6	46.2	47.1	48.8	56.0	53.9	61.8	50.9	60.4
+ Finance Costs	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.2	0.1
+ Depreciation & Amortisation	6.5	6.9	6.8	7.2	5.8	5.6	5.4	5.4	6.1	5.9	6.2	6.0
+ Other Expenses	68.5	60.5	62.7	107.8	65.1	63.6	82.6	98.4	82.4	91.8	91.1	107.5
Total Expenses	222.9	215.4	192.0	243.0	205.3	192.0	235.6	254.0	210.9	269.4	241.2	270.3
EBITDA	88.7	101.7	67.4	48.3	114.0	123.4	80.9	90.3	120.3	110.5	135.6	99.6
EBIT	82.2	94.7	60.6	41.1	108.3	117.9	75.6	84.9	114.2	104.6	129.4	93.6
Profit
PBT before Exceptional Items	88.1	99.7	62.7	43.0	111.4	121.7	78.5	88.8	119.0	108.8	133.2	97.3
+ Exceptional Items	0.0	0.0	0.0	-20.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.8
Pretax Income	88.1	99.7	62.7	22.8	111.4	121.7	78.5	88.8	119.0	108.8	133.2	129.1
+ Current Tax	22.3	29.6	16.3	12.8	28.0	29.0	20.7	22.9	30.5	32.9	32.1	31.0
+ Deferred Tax	0.2	-1.9	-0.1	-6.7	1.1	1.8	-3.4	-0.3	-0.1	-1.7	6.5	1.9
Tax Expense	22.5	27.7	16.2	6.1	29.1	30.8	17.4	22.6	30.5	31.2	38.6	33.0
Net Income	65.6	72.1	46.6	16.8	82.3	90.9	61.2	66.2	88.5	77.6	94.6	96.2
+ Net Income — Continuing Ops	65.6	72.1	46.6	16.8	82.3	90.9	61.2	66.2	88.5	77.6	94.6	96.2
+ Other Comprehensive Income	-0.5	0.9	1.3	-1.0	0.2	-2.0	-0.8	-0.7	2.4	0.9	-2.9	0.3
Total Comprehensive Income	65.1	72.9	47.9	15.8	82.5	88.9	60.4	65.5	91.0	78.5	91.7	96.5
Per Share
Basic EPS	39.50	43.40	28.00	10.11	49.60	54.76	36.86	39.87	53.34	46.74	56.99	57.92
Diluted EPS	39.50	43.40	28.00	10.11	49.60	54.76	36.86	39.87	53.34	46.74	56.99	57.92
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-0.8	-0.7	2.4	0.9	-2.9	0.3
+ Items NOT to be Reclassified to P&L	-0.7	1.2	1.8	-1.3	0.2	-2.7	-1.1	-0.9	3.2	1.2	-3.9	0.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.3	-0.2	0.8	0.3	-1.0	0.1
+ Tax on Items NOT to be Reclassified — alt tag	0.0	0.3	0.4	-0.3	0.1	-0.7	—	—	—	—	—	—
+ Tax on Items to be Reclassified — alt tag	-0.2	—	0.0	0.0	0.0	0.0	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	39.50	43.40	28.00	10.11	49.60	54.76	36.86	39.87	53.34	46.74	56.99	57.92
Diluted EPS — Continuing Operations	39.50	43.40	28.00	10.11	49.60	54.76	36.86	39.87	53.34	46.74	56.99	57.92
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	—	112.7	—	-39.1	—	278.4	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	217.8	219.6	178.6	204.7	225.4	234.0	212.3	244.8	256.5	264.0	277.6	267.5
Gross Margin %	71.42	70.84	70.75	72.11	71.91	75.55	68.26	72.25	78.95	70.63	74.93	73.54
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	88.1	99.7	62.7	43.0	111.4	121.7	78.5	88.8	119.0	108.8	133.2	97.3
− Exceptional Items (reconciliation)	0.0	0.0	0.0	-20.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.8
Net Income Adj (tax-effected)	65.6	72.1	46.6	31.6	82.3	90.9	61.2	66.2	88.5	77.6	94.6	72.5
EPS Adj	39.50	43.40	28.00	19.05	49.60	54.76	36.86	39.87	53.34	46.74	56.99	43.66
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	16.6	16.6	16.6	16.6	16.6	16.6	16.6	16.6	16.6	16.6	16.6	16.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Procter & Gamble Health Q2 FY27 results date

Procter & Gamble Health (NSE: PGHL) will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, according to the board-meeting notice it filed on 30 September 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹96.2 crore, up 45.3% from ₹66.2 crore in Q1 FY26 and up 1.6% from ₹94.6 crore in Q4 FY26. Revenue from operations was ₹364 crore, up 7.4% year on year and down 1.8% from the previous quarter.

Board-meeting notice filed: 30 September 2026
Q2 FY26 results (a year earlier): 5 November 2025
Q1 FY27 results (the latest): 6 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 2 November 2026Monday · notice filed 30 Sep
Q1 FY27 net profit: ₹96.2 Cr+45.3% vs Q1 FY26+1.6% vs Q4 FY26
Q1 FY27 revenue: ₹364 Cr+7.4% vs Q1 FY26−1.8% vs Q4 FY26
Q1 FY27 operating margin: 25.7%+0.7 pts vs Q1 FY26−9.2 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹88.5 CrRevenue ₹325 Cr
Q1 FY27 EPS (basic): ₹57.92

Questions

When will Procter & Gamble Health announce its Q2 FY27 results?

On 2 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 30 September 2026). Last year it reported Q2 FY26 on 5 November 2025.

What will Procter & Gamble Health's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹88.5 crore and revenue from operations ₹325 crore. The latest quarter, Q1 FY27, had a net profit of ₹96.2 crore and revenue of ₹364 crore.

What were Procter & Gamble Health's Q1 FY27 results?

Consolidated net profit was ₹96.2 crore, up 45.3% from ₹66.2 crore in Q1 FY26 and up 1.6% from ₹94.6 crore in Q4 FY26. Revenue from operations was ₹364 crore, up 7.4% year on year and down 1.8% from the previous quarter.

How has Procter & Gamble Health's profit changed over the last four quarters?

Net profit by quarter: ₹88.5 crore in Q2 FY26, ₹77.6 crore in Q3 FY26, ₹94.6 crore in Q4 FY26 and ₹96.2 crore in Q1 FY27. That is ₹357 crore over the four quarters, up 18.7% from ₹301 crore in the four quarters before. Revenue from operations: ₹325 crore, ₹374 crore, ₹370 crore and ₹364 crore.

What was Procter & Gamble Health's net profit in the year to June 2026?

Consolidated net profit was ₹96.2 crore in the year to June 2026 (July 2025–June 2026), up 45.3% from ₹66.2 crore in the year to June 2025. It was ₹201 crore in the year to June 2024 and ₹229 crore in the year to June 2023: down 58.1% over three years, an average fall of 25.2% a year.

What was Procter & Gamble Health's revenue in the year to June 2026?

Revenue from operations was ₹364 crore in the year to June 2026 (July 2025–June 2026), up 7.4% from ₹339 crore in the year to June 2025. It was ₹1,151 crore in the year to June 2024 and ₹1,230 crore in the year to June 2023: down 70.4% over three years, an average fall of 33.4% a year.

Where do these Procter & Gamble Health figures come from?

From Procter & Gamble Health's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.